Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 open-label inhaled S-770108 in idiopathic pulmonary fibrosis
jRCT2031210553Phase 1Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Feb 2022
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in idiopathic pulmonary fibrosis (IPF), sponsored by Shionogi & Co., Ltd. Primary endpoints: Safety and tolerability and Pharmacokinetics of pirfenidone after inhaled S-770108. Started Feb 2022; status: completed.
02
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on jRCT2031210553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210553.